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Abstract
AIM
To analyse the risk of pregnancy (a prothrombotic state) 
in patients with Budd-Chiari Syndrome (BCS). 
METHODS
Retrospective study of pregnancy in women with known 
BCS at single center from January 2001 to December 
2015. 
RESULTS
Out of 53 females with BCS, 7 women had 16 preg-
nancies. Median age at diagnosis of BCS in these 
women was 25 years (range 21-34 years). At least one 
causal factor for BCS was identified in 6 women (86%). 
Six women had undergone radiological decompressive 
treatment. All patients had anticoagulation. Six fetuses 
were lost before 20 wk gestation in 2 women. There 
were 9 deliveries over 32 wk gestation and one delivery 
at 27 wk. All infants did well. Seven babies were born 
by emergency caesarean section. There were no cases 
of thrombosis. Two patients had notable vaginal (PV) 
bleeding in 3 pregnancies. None of the patients had 
variceal haemorrhage. Two patients were diagnosed 
with pulmonary hypertension, one during pregnancy 
Submit a Manuscript: http://www.f6publishing.com
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and the other in the post-partum period. There was no 
maternal mortality.
CONCLUSION
Maternal outcomes in patients with treated BCS are 
favourable and fetal outcomes beyond 20 wk gestation 
are good. There has been increased rate of caesarean 
section. Pulmonary hypertension is an important finding 
that needs further validation. These patients should be 
managed in centers experienced in treating high-risk 
pregnancies.
Key words: Budd-Chiari syndrome; Pregnancy; Portal 
hypertension; Pulmonary hypertension; Thrombophilia
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Pregnancy is a prothrombotic state and can 
cause adverse outcome in patients with Budd-Chiari 
syndrome (BCS). In our study, maternal outcome 
in patients with known and treated BCS was good. 
However, most deliveries were carried out by emergency 
caesarean section (7/10). There was high incidence of 
placental disease leading to caesarean section. Fetal 
outcome beyond 20 wk gestation was also good. With 
careful monitoring of anti-coagulation, there were no 
cases of thrombosis and only a minority of patients had 
noteworthy bleeding complications. Development of 
pulmonary hypertension in two patients several years 
after TIPSS is an important finding that warrants further 
studies.
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INTRODUCTION
Budd-Chiari syndrome (BCS) is a rare disorder caused 
by hepatic venous outflow obstruction and resulting 
hepatic dysfunction due to sinusoidal congestion, 
ischaemic injury to the liver and portal hypertension. 
The main mechanism for BCS is thrombosis of the 
hepatic veins or of the terminal portion of the inferior 
vena cava[1,2]. The management using a stepwise 
regimen is largely successful with anticoagulation 
and interventional radiology alone. Stepwise regimen 
includes; (1) anticoagulant therapy for an indefinite 
period of time; (2) angioplasty or stenting for stenosis 
of hepatic veins; and (3) decompressive techniques 
[surgical shunt or transjugular intrahepatic porto-
systemic shunts (TIPSS)], for patients who are non-
responsive to medical treatment or not candidates for 
angioplasty/stenting[3]. TIPSS has a lower morbidity 
and mortality rate than surgery and is a preferred 
approach. The outcomes are favourable with 10-year 
survival approaching 90%[4,5].
Usually multiple risk factors for venous thromboem-
bolism are present in patients with BCS[1,6-8]. In one 
study, 84% of 163 patients with BCS had at least one 
thrombotic risk factor, and 46% of these patients had 
more than one prothrombotic risk factor; the most 
common was myeloproliferative neoplasia (MPN) 
(49% of 103 tested patients)[9]. In another study of 
43 women with BCS, at least one thrombotic risk 
factor (not considering pregnancy as risk factor) was 
identified in 40 women (93%) including MPN in 56% 
of study participants[10]. Other thrombotic risk factors 
include mutation in Factor V Leiden and prothrombin 
gene, protein C, protein S or antithrombin deficiency, 
antiphospholipid syndrome, hyperhomocysteinemia 
and paroxysmal nocturnal haemoglobinuria. BCS may 
also be a complication of systemic vasculitides such as 
Bechet’s disease[11].
BCS mainly affects women of childbearing age and 
pregnancy can be a crucial issue. There is conflicting 
data on prevalence of pregnancy related BCS. A sys-
tematic review and meta-analysis of twenty studies 
demonstrated a pooled prevalence of pregnancy-related 
BCS of 6.8%[12]. However another study showed that 
pregnancy is unlikely to cause BCS in the absence of 
other thrombotic risk factors[10]. 
Pregnancy is a hypercoagulable state and earlier 
studies reported that women with BCS could be at 
risk of developing severe exacerbation of their under-
lying disease during pregnancy[13,14]. Rautou et al[15] 
conducted a study on outcome of pregnancy in women 
with known and treated BCS and concluded that good 
maternal outcome could be achieved with current 
treatment modalities and close surveillance of BCS. 
Therefore, BCS cannot be considered a contraindi-
cation to pregnancy in stable patients with well-con-
trolled disease.
As the available literature on pregnancy compli-
cations in women with known BCS remains scarce, we 
performed this study of women treated at our tertiary 
centre for BCS who had become pregnant.
MATERIALS AND METHODS
We used the definitions related to outcome of pre-
gnancies as previously described by Rautou et al[15]: 
(1) date of diagnosis of BCS: the first imaging moda­
lity showing an obstructed venous outflow tract; and 
(2) miscarriages: A spontaneous loss of pregnancy 
before 20 weeks’ of gestation. Outcome of the pre-
gnancy: (1) favourable: Live birth occurred at 32 or 
more completed weeks of gestation, with a healthy 
infant and no serious obstetrical complication (bar 
intrahepatic cholestasis); and (2) poor: Otherwise 
pregnancy outcome. Rotterdam prognostic index was 
calculated as previously described[16]. 
The electronic records of all female patients dia-
947 July 28, 2017|Volume 9|Issue 21|WJH|www.wjgnet.com
gnosed with BCS between January 2001 and Decem-
ber 2015 at our tertiary care referral center were 
retrospectively analysed. The data was collected 
prospectively and radiology records of these patients 
were also searched. Those that became pregnant during 
the follow-up for BCS were included in the study. Patients 
in whom pregnancy occurred before BCS was diagnosed 
were excluded. 
All patients were tested for the known prothro-
mbotic factors. Combined oral contraceptive pill (OCP) 
use within the 3 mo preceding diagnosis of BCS was 
considered a thrombotic risk factor.
Where possible, patients had pre-pregnancy coun-
selling and were made aware of the potential com-
plications that may occur during pregnancy. Patients 
with known varices or portal hypertension had pre-
pregnancy gastroscopy to ensure varices had been 
treated. These patients had further gastroscopies for 
variceal surveillance during second trimester. Patients 
with TIPSS had regular abdominal ultrasound to ensure 
patency of the TIPSS. The patients were monitored in a 
joint haematological/obstetric clinic. 
Given the risk of embryopathy and fetal loss associ-
ated with warfarin, low molecular weight heparin 
(LMWH) was substituted for warfarin as soon as pre-
gnancy was diagnosed, or prior to conception in one 
patient who had two in-vitro fertilisation treatments. 
The dose of LMWH was adjusted to maintain therapeutic 
factor Xa activity in selected cases under haematology 
supervision. LMWH treatment was replaced by warfarin 
following the delivery. 
RESULTS
Baseline characteristics
Fifty-three female patients under follow-up for BCS 
were identified. Out of these, 7 patients had 16 pre­
gnancies during the study period. 
Median age of diagnosis of BCS was 25 years (range 
21­34 years). Five (71%) patients had abdominal pain 
as the presenting complaint and symptoms were mainly 
chronic in nature. One patient had variceal haemorrhage 
and three patients had ascites on presentation of BCS. 
None of them had hepatic encephalopathy. None of the 
patients had other significant co­morbidities when the 
diagnosis of BCS was established. The characteristics of 
these patients including Rotterdam and Clichy scores at 
the time of diagnosis of BCS are given in Table 1. The 
laboratory values were stable at time of conception in 
all patients and ascites had resolved.
BCS was managed by anticoagulation therapy and 
radiological interventions with the aim to recanalise any 
outflow obstruction. Six out of the 7 patients underwent 
liver decompression procedures before conception. 
Procedures included dilatation of right hepatic vein 
(one patient), TIPSS (in four patients) and right hepatic 
vein stenting (one patient). One patient did not have 
any intervention for decompression and was managed 
with oral anticoagulation (warfarin) alone. All patients 
had anticoagulation. None of the patients in our series 
required surgical porto-systemic shunting or liver trans-
plantation as a definite treatment of BCS.
At least one causal factor for hepatic vein obstru-
ction was identified in 6 of these 7 women (86%). JAK 
2V617F mutation alone was seen in 2 patients; factor 
V Leiden alone in one; JAK 2 mutation and factor V 
Leiden in one patient; JAK 2 mutation and OCP use in 
one patient; and factor V Leiden and OCP use in one 
patient. One patient did not have any identifiable risk 
factor. 
Pregnancy course
Median age at conception was 32 years (range 23-39). 
Median time between diagnosis of BCS and conception 
was 5 years (range 3 mo-13 years). Follow up after the 
diagnosis of BCS in the seven women with pregnancies 
was for a median of 7 years (range 3­14 years). All 
patients that became pregnant had well compensated 
liver disease at the time of each conception and 
stigmata of decompensation of liver disease (ascites, 
in majority of patients at presentation) were no longer 
present at the time of any pregnancy. Gestational 
course is detailed in Table 2. 
Aspirin (along with LMWH) was administered to 
one patient in 2 pregnancies (patient 6) for Essential 
Thrombocytosis. This patient was also treated with 
interferon for JAK 2 positive MPN. No patient was 
treated with beta-blockers during pregnancy.
Six out of the 16 (38%) pregnancies miscarried 
with fetal loss before 20 wk gestation. Six miscarri-
ages/failed pregnancies occurred in 2 patients. One 
miscarried at 5 wk when she presented with vaginal 
bleeding. She was not aware of the pregnancy. The 
other patient had 5 miscarriages over a 9-year period. 
Two out of 5 were after the first trimester and these 
were attributed to cervical weakness and, therefore, 
she had cervical sutures in the following pregnancies 
(after 13 wk of gestation) leading to two successful 
deliveries. 
Out of the 10 pregnancies reaching beyond 20 
wk gestation, there were 3 vaginal deliveries and 7 
caesarean sections. There was one very preterm birth 
at 27 wk and 5 preterm deliveries between 32 and 35 
wk gestation, all with favourable neonatal outcomes. 
Four pregnancies resulted in delivery after 36-wk 
gestation, again all with favourable outcome.
Seven (70%) infants were delivered via emergency 
caesarean sections. Indications for caesarean sec-
tion were varied, including fetal distress in three pre-
gnancies; pre-eclampsia in one, breech presentation in 
one, bleeding from placenta praevia in one patient and 
difficult labour due to cervical suture in one patient.
Specific complications
Four patients developed intrahepatic cholestasis of 
pregnancy (ICP) in five pregnancies and they were 
treated with ursodeoxycholic acid. One patient had 
pre-eclampsia needing emergency caesarean section. 
Khan F et al . Pregnancies in patients with BCS
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Significant PV bleeding occurred after 3 preg-
nancies in 2 patients (patients 3 and 6 in Tables 1 and 
2). One patient (patient 3) had a primary post-partum 
haemorrhage secondary to a retained placenta that 
was surgically removed. The other patient (patient 
6) had a complicated first pregnancy with placental 
abruption at 27 wk gestation and needed emergency 
caesarean section. In her second pregnancy, she 
had secondary postpartum haemorrhage following 
caesarean section for suspected placental abruption. 
It was treated with surgical evacuation of uterine clot 
and insertion of a Rusch Balloon. There were no cases 
of variceal haemorrhage. 
One patient, (patient 5) underwent regular gastros-
copies for banding of (non-bleeding) oesophageal 
varices. That patient was not treated with beta-blo-
ckers during pregnancy. There were no cases of throm-
bosis in any of the pregnancies.
  Patient ID 1 2 3 4 5 6 7
  Age at diagnosis (yr) 34 21 30 21 31 24 25
  Symptoms at 
  presentation 
Ascites Oesophageal 
variceal 
haemorrhage, 
abdominal 
pain
Abdominal pain; 
ascites 
Abdominal 
pain, ascites
Abdominal pain, fever, 
mouth ulcers
Ascites, renal 
failure and sepsis 
(ITU admission)
Abdominal 
pain 
  Risk factors for BCS JAK 2 positive MPD; 
OCP
JAK 2 positive 
mutation
None identified Factor V Leiden; 
OCP
JAK2 positive 
MPD (Essential 
Thrombocythaemia); 
Factor V Leiden 
JAK 2 positive 
mutation
Factor V 
Leiden 
  Encephalopathy None None None None None None None 
  Ascites Moderate Mild Mild Mild None initially Severe Moderate 
  INR       1.7        1.4        1.2        1.3      1.7        1.4        1.5
  Albumin (g/L) 28   37   49   49 49   25   26
  Bilirubin (umol/L) 19   18   20   18 11    51   32
  ALT (U/L) -   31 -   57 - -        - 
  AST (U/L) 134 49   20   34 27 277   43
  Urea (mmol/L)       2.7       2.3       2.9       4.7      2.9        4.4      2
  Creatinine (mmol/L)   72   43   70   68 51   92   70
  Sodium (mmol/L) 143 137 143 142                  140 130 133
  MELD   19   14     6   10      12.37    14   17
  UKELD   53   53   48   49 49   49   55
  Hb (g/L) 137 121 155 128                  150 147   88
  WCC (109/L)       7.9       9.6      10.9        5.7      5.7      28.8        6.8
  Platelets (109/L) 345 183 307 247                  411 400 226
  Rotterdam PI 1.116           0.072          1.12         0.07       1.08           1.244            1.168
  Clichy PI        4.39          1.99         3.13         4.04       3.44         7.54          7.55
  Liver biopsy Not done Not done Not done Suggestive of 
hepatic vein 
obstruction
Consistent with 
Hepatic venous outflow 
obstruction
Not done Not done 
  Level of obstruction Left hepatic vein Hepatic vein Hepatic vein Hepatic Vein Right Hepatic Vein Left Hepatic vein Hepatic vein
  Radiological 
  intervention 
TIPSS TIPSS None Angioplasty 
and Stenting to 
Hepatic vein
Right Hepatic Vein 
dilatation 
TIPSS TIPSS
  Type of TIPSS Viatorr (covered) Viatorr 
(covered)
- - - Memotherm, then 
Viatorr 
Memotherm 
(Uncovered) 
  Medications post 
  intervention 
Warfarin Warfarin     N/A Warfarin Warfarin Warfarin, 
Interferon 
Warfarin 
  Duration of follow 
  up (yr)
4 5 7 3 13 14 14
  Comments/
  complications 
  following 
  intervention
TIPSS Stent 
redilatation after a 
week of insertion
TIPSS stent 
stenosis - 
needed to be 
re-dilated in 
2 yr
Maintained 
on oral 
anticoagulation 
(warfarin) and 
did not require 
any intervention
Vascular 
Wallstent was 
re-canalized 
after 2 yr
Inferior RHV dilated 5 
yr after the diagnosis 
(developed ascites and 
had compliance issues). 
Bleeding from 
hepatic nodule 
(with INR > 
9). Managed 
conservatively. 
Later stent was 
changed to a 
covered one for 
TIPSS stenosis
-
Table 1  Baseline characteristics of the patients at presentation
MPD: Myeloproliferative disorder; TIPSS: Trans-jugular intrahepatic posto-systemic shunt; OCP: Oral contraceptive pills; INR: International normalised 
ratio; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; MELD: Model for end-stage liver disease; UKELD: United Kingdom model for 
end-stage liver disease; Hb: Haemoglobin; WCC: White cell count.
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Two patients (patients 6 and 7) developed sym­ ptoms of pulmonary hypertension (PH) during the 
  Patient  
  No.
Pregnancy 
No.
Age at 
gestation 
(yr)
Anticoagulation 
during pregnancy
Mode of 
delivery
Weeks 
gestation
Birth weight Foetal/infant condition Maternal condition
  1   1 37 LMWH Vaginal 36 2645 g Neonatal jaundice, 
treatment with 
antibiotics for suspected 
infection
  2   2 24 LMWH Emergency 
caesarean 
section 
35 2140 g Fetal distress (reduced 
foetal movements)- 
Healthy baby
ICP
OGDs during pregnancy, no 
varices seen
  3   3 35 LMWH Vaginal 
delivery
35 2600 g Mild Jaundice In-vitro fertilization treatment
  3   4 37 LMWH Vaginal 
delivery
37 2450 g Healthy In-vitro fertilization treatment
Primary post-partum 
haemorrhage secondary to 
retained placenta that was 
surgically evacuated
  4   5 23 LMWH Caesarean 
section
37 2645 g Fetal distress - Healthy 
baby post delivery
…
  5   6 36 LMWH and 
Aspirin (switched 
from warfarin 
and Hydroxyurea 
at 22 wk when 
pregnancy was 
diagnosed)
Emergency 
caesarean 
section
37 3115 g Breech presentation Had several gastroscopies (OGD) 
and banding to Oesophageal 
Varices during pregnancy
  5   7 39 Warfarin Miscarriage   5 - - PV bleeding; was not aware of 
conception
  6   8 31 LMWH Emergency 
Caesarean 
Section
27 Not available Healthy boy Bleeding secondary to placental 
abruption
ICP from 25 wk
  6   9  37 LMWH, Aspirin, 
interferon for MPD 
(Myeloproliferative 
disorder)
Emergency 
Caesarean 
section 
35 Not available Fetal distress. Healthy 
baby 
ICP
Minor subchorionic bleeding at 
12 and 23 wk. LMWH reduced, 
aspirin stopped temporarily. 
Changes resolved on subsequent 
scans. Presentation with PH and 
suspected placental abruption at 
35 wk
Secondary post-partum 
haemorrhage treated with 
surgical of uterine clot evacuation 
and Rusch Balloon
  7 10 25 LMWH Miscarriage   9 - - - 
  7 11 27 LMWH Miscarriage 20 - Congenital pneumonia 
and mild amnionitis 
Weakness of cervix; 
  7 12 28 LMWH Miscarriage 19 - - Placental abruption
Weakness of cervix; 
Placental abruption
  7 13 29 LMWH Emergency 
Caesarean 
Section
35 2974 g Healthy boy Dyspnoeic during 3rd Trimester; 
ICP in 20 wk onwards; 
C-Section for difficult labour 
(cervical suture could not be 
removed)
  7 14 31 LMWH Failed 
Pregnancy
10 - - Surgical removal of retained 
products of Contraception
  7 15 33 LMWH Miscarriage   7 - - - 
  7 16 34 LMWH Emergency 
Caesarean 
Section
35 2440 g Healthy boy Pre-eclampsia; 
Breathlessness during 3rd 
trimester, PH diagnosed after 
pregnancy
Table 2  Gestational course and perinatal complications in 16 pregnancies 
LMWH: Low molecular weight heparin; ICP: Intrahepatic cholestasis of pregnancy; PH: Pulmonary hypertension.
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course of pregnancy and are described as follows. 
Case 1 
This patient had second pregnancy at the age of 37 
years (13 years after the diagnosis and treatment of 
BCS). She had minor subchorionic bleeding noted on 
ultrasound during pregnancy. At 35 wk of gestation, this 
patient had emergency caesarean section for suspected 
placental abruption and developed respiratory failure 
post operatively. Trans-thoracic echocardiography (TTE) 
suggested PH with pulmonary artery systolic pressure 
estimated at 60-65 mmHg. CT scan excluded pulmonary 
embolism and showed patent TIPSS and mild spleno-
megaly. Right heart catheterisation confirmed the 
presence of PH with mean pulmonary artery pressure 
(mPAP) of 37 mmHg and pulmonary artery wedge 
(PAWP) pressure of 12 mmHg. She is being treated with 
Sildenafil (phosphodiesterase inhibitor) and Macitentan 
(endothelin receptor antagonist) for PH. Follow up 
investigations demonstrated improved exercise toler-
ance with no significant limitations in activities of daily 
living (patient 6; Tables 1 and 2). 
Case 2
This patient delivered her second child at 34 years of 
age, 9 years after the diagnosis and treatment of BCS. 
Caesarean section was performed at 35-wk gestation 
for pre-eclampsia. Dyspnoea on exertion was noted 
during the pregnancy and six months after delivery 
she was admitted with right heart failure. CTPA 
excluded pulmonary embolus; but noted dilatation of 
pulmonary artery, moderate to severe dilatation of 
right atrium and moderate dilation of right ventricle 
with a degree of right ventricular hypertrophy. TIPSS 
was shown to be patent. TTE demonstrated severe PH, 
severely dilated right ventricle with impaired systolic 
function. Right heart catheterisation confirmed PH 
(mPAP 53 mmHg, PAWP 11 mmHg). The patient has 
been treated with sildenafil and intravenous Iloprost 
(along with warfarin) for PH and is being considered 
for lung transplantation assessment (patient 7; Tables 
1 and 2).
DISCUSSION
The majority of the patients affected by BCS in Western 
countries are women of childbearing age[1,16], with the 
peak incidence in the third decade for women and 
in the fourth decade for men[17]. Fertility is generally 
unaffected in women with BCS as only a minority 
becomes cirrhotic. 
Several previously reported observations suggest 
that pregnancy in BCS women could cause deterioration 
of the liver disease and pregnancy was associated with 
development of ascites in several women with known 
BCS[17­19]. Rautou et al[15] showed that the maternal 
outcome, in 14 women with 24 pregnancies is good 
in women becoming pregnant after the diagnosis and 
treatment of BCS. All mothers were alive at a median 
follow-up of 34 mo after last delivery and only one of 
them required liver transplantation after 73 mo follow­ 
up. 
In our series, there were no thrombotic events 
occurring during pregnancy or the postpartum period. 
This is comparable to previous study[15] where 2 of 
17 pregnancies on anticoagulation therapy were 
complicated by portal vein thrombosis[15]. Subclavian 
and portal venous thrombosis has been reported 
in a pregnant patient with known and treated BCS 
secondary to (JAK 2 negative) essential thrombocytosis 
on anticoagulation[20].  
Two patients had notable bleeding related to 3 
deliveries in contrast to 6 patients with 7 bleeding 
episodes during pregnancy or postpartum in the 
previous study[15], signifying the importance of careful 
management of anticoagulation in pregnancy. 
Both of our patients who developed pulmonary 
hypertension (mPAP ≥ 25 mmHg at rest) had the 
diagnosis of BCS and insertion of TIPSS several years 
ago. TIPSS has been regarded as a cardiac stress by 
suddenly increasing the preload leading to increased 
cardiac diastolic volumes and diameters, and a transient 
PH for 3-6 mo[21,22]. It is usually accommodated rapidly 
and is then associated with a reduction in systemic 
vascular resistance and a reduction in afterload[22]. 
However, development of PH after one and half years 
following TIPSS insertion has been reported[23]. In a 
recent study looking at the long-term cardiopulmonary 
outcome following TIPSS in cirrhotic patients, authors 
found higher prevalence of PH in the TIPSS group, 
1 to 5 years post TIPSS implantation[24]. Although 
the patients in that study[24] could could have had 
associated cirrhotic cardiomyopathy, conversely 
there appears to be a potential long-term risk of 
development of PH in non-cirrhotic patients with a 
patent, functional TIPSS. Therefore, further studies on 
the interactions of TIPSS and cirrhotic cardiomyopathy 
are warranted[25].
PH has also been reported as a common finding 
in MPN[26]. This possible association of PH with MPN 
has also been suggested by small case series and 
studies[27­30] and the exact incidence and prevalence of 
PH in this group of patients remain poorly defined[31]. 
MPN could possibly have had an impact on the 
development of PH in one of our patients (patient 6).
Current recommendations are to offer endoscopic 
screening for varices in patients with portal hyper-
tension, when conception is planned and during the 
second trimester if not already on prophylaxis. One 
patient (patient 2) who had originally presented with 
variceal haemorrhage underwent gastroscopy in second 
trimester for variceal screening and was found not to 
have varices. Another patient (patient 5, who had right 
hepatic vein dilatation) had several gastroscopies for 
oesophageal variceal band ligation during pregnancy. 
None of the patients suffered variceal bleeding during 
pregnancy or were administered non-selective beta-
blockers during pregnancy given concerns regarding 
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use of beta-blockers in pregnancy[32,33].  
The number of deliveries by caesarean section was 
higher in our group of patients (7 in 10 deliveries, 70%) 
than in the general obstetric population in England 
(26%)[34] and the previous study (8 caesarean sections 
in 17 pregnancies, 47%)[15]. Although some of the 
indications for caesarean section were clearly not related 
to the presence of BCS (e.g., breech presentation, 
placenta praevia), the high incidence of placental 
disease (abruption, pre-eclampsia, fetal distress) 
leading to caesarean section may be related to the 
underlying causative aetiology of the BCS. Therefore, 
close maternal and fetal surveillance for placental 
disease should be considered in these patients. 
Interestingly, for unknown reasons, incidence of 
ICP has been higher in our patients (4 patients in 5 
pregnancies) than the normal obstetric population 
(0.7%­1.5%)[35,36]. 
Our study supports that the maternal outcome is 
good in women becoming pregnant after the diagnosis 
and treatment of BCS. This favourable maternal 
outcome is likely to be attributable to improvement in 
management of BCS including effective decompressive 
treatment, management of the underlying conditions, 
anticoagulant therapy with careful follow-up; and 
management of pregnancy and delivery in multi-
disciplinary settings. A possibly decreased level of 
significant bleeding and no thrombosis implies the 
benefits of very close monitoring of anticoagulation 
through joint clinics.
In contrast to the good overall maternal outcome 
seen in our set of patients, the livebirth rate of 62.5% 
is lower than in the general obstetric population 
(84%[37] and 85%-88%[38]), but is better than earlier 
reports and in line with the finding of Rautou et al[15]. 
Importantly, failed pregnancies occurred in only 2 
out of 7 patients. One patient (patient 7) had 5 fetal 
losses over a 9-year period (83% of the incomplete 
pregnancies reported here).
Our study supports the conclusion that BCS cannot 
be considered a contraindication to pregnancy in stable 
patients. Development of PH is an important finding 
that needs further validation. Such patients should 
be managed at tertiary level care centres with multi-
disciplinary involvement.  
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long-term risk of development of PH in non-cirrhotic patients with a patent, 
functional TIPSS that needs further exploration. There was higher incidence 
of deliveries by caesarean section (7 in 10 deliveries) in this study group and 
was attributed to the placental disease that could be related to the underlying 
causative aetiology of BCS. 
Applications
This study supports that the maternal outcome in women becoming pregnant 
after the diagnosis and treatment of BCS is good. Fetal outcome beyond 20 
wk gestation is also good. Close maternal and fetal surveillance for placental 
disease should be considered in these patients. Development of PH post TIPPS 
is an important finding that needs further validation. Such patients should be 
managed at tertiary level care centres with multi-disciplinary involvement. 
Terminology
The BCS is named after a British Physician, George Budd in 1845 and a 
pathologist Hans Chiari who first described the features of BCS caused by the 
hepatic venous outflow obstruction in 1899. TIPSS-transjugular intrahepatic 
portosystemic shunt or transjugular intrahepatic portosystemic stent shunting 
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